Oncolytics Biotech To Present At Cancer Research Annual Meeting Apr. 10-15
Oncolytics Biotech To Present At Cancer Research Annual Meeting Apr. 10-15
SAN DIEGO and CALGARY, AB, March 10, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will present updated clinical data from its AWARE-1 window-of-opportunity study in patients with early-stage breast cancer, as well as results from preclinical studies evaluating pelareorep-based combination therapies, in poster presentations during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021.
Details on the posters and corresponding abstracts are shown below. All posters will be made available on the conference website on April 10, 2021.
海报和相应摘要的详细内容如下所示。所有海报将于2021年4月10日在大会网站上公布。
Title: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (AWARE-1)
Session Type: E-Poster Session
Session Category: Phase II Clinical Trials
Session Title: Phase II Clinical Trials
Abstract Number: CT191 (late-breaking abstract)
标题：在早期乳腺癌中应用阿替唑珠单抗和溶瘤病毒Pelareorep的机会窗研究(AWARE-1)会话类型：电子海报会议会话类别：第二阶段临床试验会话标题：第二阶段临床试验摘要编号：CT191(最新摘要)
Oncolytics will provide details on the results described in this abstract following publication of the abstract and corresponding poster at the AACR Annual Meeting in April, in accordance with conference embargo policies regarding late-breaking abstracts.
Oncollytics公司将根据有关最新摘要的会议禁运政策，在4月份的AACR年会上发表摘要和相应的海报后，提供本摘要中描述的结果的细节。
Title: Mechanisms of therapeutic synergy between pattern recognition response agonists and cdk4 inhibitors
Session Type: E-Poster Session
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Cell Cycle
Abstract Number: 1960
标题：模式识别反应激动剂与CDK4抑制剂协同治疗的机制会话类型：电子海报会议会话类别：分子和细胞生物学/遗传学会话标题：细胞周期摘要编号： 1960
New preclinical studies identify the mechanisms of therapeutic synergy between pelareorep and the CDK4/6 inhibitor palbociclib. Data show that combining pelareorep with palbociclib augmented pelareorep-induced endoplasmic reticulum (ER) stress signaling and increased innate immune activation and effector function. These results suggest that this combination can be exploited to enhance anti-cancer efficacy with pro-immunogenic consequences and suggest that pelareorep may have the potential to broaden the therapeutic applicability of CDK4/6 inhibitors.
新的临床前研究确定了盆腔瑞普和CDK4/6抑制剂Palbociclib之间的治疗协同作用的机制。数据显示，联合使用Pelarerep和Palbociclib可增强Pelareorep诱导的内质网(ER)应激信号，并增强先天免疫激活和效应功能。这些结果表明，这一组合可用于增强抗癌效果，并具有促进免疫原性的作用，并提示Pelareorep可能具有扩大CDK4/6抑制剂治疗适用性的潜力。
The full text of the corresponding abstract is available on the AACR Annual Meeting 2021 website (link).
相应摘要全文可在AACR 2021年年会网站(链接).
Title: Talazoparib interacts with oncolytic reovirus to enhance death-inducing signaling complex (DISC)-mediated apoptosis and immune response
Session Type: E-Poster Session
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Apoptosis
Abstract Number: 1932
标题：他唑帕利与溶瘤呼肠孤病毒相互作用增强死亡诱导信号复合体(DISC)介导的细胞凋亡和免疫应答会话类型：电子海报会议会话类别：分子和细胞生物学/遗传学会话标题：细胞凋亡摘要编号： 1932
New preclinical data show that combining pelareorep with talazoparib, a clinically approved poly(ADP)-ribose polymerase 1 (PARP-1) inhibitor, led to enhanced anti-tumor efficacy that correlated with an increased immune response in murine tumor models. These data provide a scientific rationale for combining pelareorep with PARP-1 inhibitors to exploit immunogenic responses in cancer treatment.
新的临床前数据显示，与临床批准的聚(ADP)核糖聚合酶1(PARP-1)抑制剂他拉唑帕利联合使用，可以增强抗肿瘤效果，这与增强小鼠肿瘤模型的免疫反应有关。这些数据为联合Pareorep和PARP-1抑制剂以开发癌症治疗中的免疫原性反应提供了科学依据。
The full text of the corresponding abstract is available on the AACR Annual Meeting 2021 website (link).
相应摘要全文可在AACR 2021年年会网站(链接).
About AWARE-1
AWARE-1 is an open label window-of-opportunity study in early-stage breast cancer enrolling 38 patients into five cohorts:
关于Aware-1Aware-1是一项针对早期乳腺癌的开放式标签机会窗研究，将38名患者纳入5个队列：
- Cohort 1 (n=10), HR+ / HER2- (pelareorep + letrozole)
- Cohort 2 (n=10), HR+ / HER2- (pelareorep + letrozole + atezolizumab)
- Cohort 3 (n=6), TNBC (pelareorep + atezolizumab)
- Cohort 4 (n=6), HR+ / HER2+ (pelareorep + trastuzumab + atezolizumab)
- Cohort 5 (n=6), HR- / HER2+ (pelareorep + trastuzumab + atezolizumab)
- 队列1(n=10)，HR+/HER2-(培拉罗普+来曲唑)
- 队列2(n=10)，HR+/HER2-(Pelareorep+letrozole+atezolizumab)
- 队列3(n=6)，TNBC(Pelareorep+atezolizumab)
- 队列4(n=6)，HR+/HER2+(pelareorep+trastuzumab+atezolizumab)
- 队列5(n=6)，HR-/HER2+(pelareorep+trastuzumab+atezolizumab)
The study combines pelareorep, with or without atezolizumab, and the standard of care therapy according to breast cancer subtype. Patients are biopsied as part of their initial breast cancer evaluation, then again on day three following initial treatment, and a final tissue sample after three weeks, on the day of their mastectomy. Data generated from this study are intended to confirm that the virus is acting as a novel immunotherapy and to provide comprehensive biomarker data by breast cancer subtype. The primary endpoint of the study is overall CelTIL (a measurement of cellularity and tumor-infiltrating lymphocytes). Secondary endpoints for the study include CelTIL by breast cancer subtype, safety and tumor, and blood-based biomarkers.
这项研究结合了培拉罗普，使用或不使用阿唑珠单抗，以及根据乳腺癌亚型的护理治疗标准。作为最初乳腺癌评估的一部分，患者接受活检，然后在最初治疗后的第三天再次进行活检，并在三周后的乳房切除当天进行最终组织样本。这项研究产生的数据旨在证实该病毒正在作为一种新的免疫疗法，并按乳腺癌亚型提供全面的生物标志物数据。这项研究的主要终点是总体CelTIL(细胞密度和肿瘤浸润性淋巴细胞的测量)。这项研究的次要终点包括乳腺癌亚型、安全性和肿瘤的CelTIL，以及基于血液的生物标记物。
For more information about the AWARE-1 study, refer to https://clinicaltrials.gov/ct2/show/NCT04102618.
有关-1\f25 Aware-1\f6研究的更多信息，请参阅Https://clinicaltrials.gov/ct2/show/NCT04102618.
译文内容由第三方软件翻译。